



January 10, 2021

CARDIOCOMM SOLUTIONS PROVIDES FINANCIAL UPDATE

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm” or the “Company”), a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, is confirming the appointment of a new Chief Financial Officer and completion of a debt to equity settlement.

On December 29, 2020 the Company announced that two of its four lenders had exercised their right to convert loans that had been recently renewed under a two year term, to equity. With the approval of the TSX-v, CardioComm confirms the issuance of an aggregate of 5,000,000 common shares of the Company (each, a “Share”) to settle \$250,000 worth of debt. The Shares are subject to a four month hold period that expires May 9, 2021, in accordance with applicable securities laws.

CardioComm Solutions, Inc. also confirms the appointment of Ms. Josée Bertrand as the Company’s Chief Financial Officer. Ms. Bertrand is an accomplished, results-driven senior accounting and financial management executive. She brings more than 30 years of progressive experience in finance and operations management in relevant industry sectors. Ms. Bertrand received her Bachelor of Business Administration and Commercial Studies from the University of Western Ontario and holds a CPA designation.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites at www.cardiocomm solutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocomm solutions.com
investor.relations@cardiocomm solutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.